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Section 1. Introduction
Drosophila melanogaster has an expansive and impressive history as a model organism.
From its central role in three Nobel prize winning studies to its modern day usage in
cutting-edge research related to aging and Alzheimer’s [1], the Drosophila model has
proven itself to be one of the greatest assets to science and medicine. The often-used
murine model for metabolic research suffers from high maintenance costs and lengthy
developmental time; D. melanogaster makes a generally more efficient model because of
the fruit flies’ conveniently short life cycle and inexpensive upkeep. Additionally,
Drosophila is superior at performing genetic screens, which is particularly useful when
researching metabolism, which has many genetic influences.
There is a high degree of conservation among the neuroendocrine and metabolic
architecture of members of the animal kingdom. The universal necessity to maintain
blood glucose homeostasis means that the insulin signaling pathway and the storage of
excess glucose in the form of glycogen and triacylglycerides are some of these
evolutionary ancient and highly conserved pathways. Thus our understanding of human
metabolic diseases can be productively advanced through use of animals that are much
more distantly related to humans than mammals. Drosophila seems a potentially ideal
model organism for this research.
One of the most widespread metabolic diseases in the United States of America is type II
diabetes mellitus. The majority of Americans with diabetes have been diagnosed with
type II and the number affected grows every year since risk factors include advanced age
and calorie-excessive diet. Despite its prevalence, not much is known about how to best
treat this disease or other metabolic diseases. Modern anti-diabetic treatment and
prevention options are suboptimal and vary in efficacy. Discovery of and research into
new treatment options is essential to optimize treatment of the disease. The use of the
proven model organism, D. melanogaster, in a drug screen will help to expedite these
discoveries.
1.1 Drosophila in metabolic research
This endeavor is not without precedent. A number of studies have already been
performed which employ Drosophila as a model for metabolic disease. There has been
substantial research done which indicates mammalian insulin and Drosophila insulin-like
peptides (dILPs) perform similar functions and participate in analogous pathways,
including glucose storage regulation and certain aging pathways [2,3]. Further
Drosophila research regarding the specifics of blood glucose homeostasis has yielded
informative results [4]. This success has promoted interest in using Drosophila to study
metabolic disorders that result in a person’s inability to autonomously maintain this
homeostasis.
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Of particular interest is the development of diet-induced metabolic disease. Insulin
resistance is the inability of cells to respond to insulin and is the primary characteristic of
type II diabetes mellitus. This insulin resistant phenotype (as well as obesity) was
observed in flies fed high-sugar diets [5]. This result is consistent with those obtained by
previous studies in our lab. In these studies it was shown that flies overfed on yeast or
sugar experience weight gain and are observed to be insulin resistant [6]. These flies are
similarly seen to have decreased longevity. Flies fed on 5% yeast or sucrose may be
healthier than those fed on 30% yeast or sucrose - additional data also supports this idea.
Insulin resistance and its effect can be assessed using a number of techniques. Of these
techniques, one of the most easily quantifiable is the metabolic storage phenotype. Insulin
resistance results in abnormal trends in glucose storage. To monitor these trends, the
concentration of glucose, glycogen, and trehalose can be measured. The effect of diet on
the glucose storage phenotype of Drosophila and results are summarized in figure 2 and
figure 3. Note how dramatically different the “healthy” 5% fed flies are from the
“unhealthy” 30% fed flies.

Figure 1. Effects of a high protein diet on Drosophila metabolism. Following eclosion, adult flies were
raised for ten days on a diet of sucrose (15%, all contents w/V) and differing amounts of yeast extract as
indicated. Flies were harvested, weighed and their glucose, glycogen and trehalose levels determined in
whole body extracts in at least triplicate. Flies show weight gain with increased food content when on nonstarvation diets (1-way ANOVA pb0.0001; with post-test for linear trend p=0.0023; asterisk: t-test for the
weight drop between 15% and 30%: p=0.0038). Glycogen and trehalose levels decline with increasing food
content (1-way ANOVA with post-test for linear trend: pb0.0001and p=0.0108, respectively), but no
changes in glucose levels are observed. Shown is a representative of two independent experiments. Figure
and legend taken directly from Morris et al [6].
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Figure 2. Effects of a high sucrose diet on Drosophila metabolism. Following eclosion, adult flies were
raised for ten days on a diet of yeast extract (15%, all contents w/V) and differing amounts of sucrose as
indicated. Flies were harvested, weighed and their glucose, glycogen and trehalose levels determined in
whole body extracts in at least triplicate. Flies show weight gain with increased food content (1-way
ANOVA pb0.0001; with post-test for linear trend pb0.0001), but no changes in stored carbohydrates when
on non-starvation diets. Shown is a representative of two independent experiments. Figure and legend taken
directly from Morris et al [6].

The major implications of figures 2 and 3 are evident from examining only the effects of
5% (“healthy”) and 30% (“overfed”) diets. As the yeast extract content of their diet
increases, fly mass increases, total glucose levels stay constant, while glycogen and
trehalose levels decrease. As the sucrose content of their diet increases, fly mass
increases, while glucose, glycogen, and trehalose levels stay essentially constant. These
trends will serve as the baseline for assessing drug effect on the flies.
The initial drug screen therefore is limited to the two pairs of 5% and 30% yeast and
sucrose foods to optimize efficiency.
1.2 My project goals: Finding novel anti-diabetic treatments
The goal of this study is to use this previously published data as a baseline to assess the
efficacy of commonly prescribed human anti-diabetic medications on Drosophila. The
known anti-diabetic compounds that I will use on the flies are glibenclamide and
rosiglitizone. Ria Chaabra, a high school student involved in the lab this summer, had a
personal interest in traditional Indian medicine. She chose to investigate the effect of
different natural compounds in her own naturalistically inspired “drug” screen following
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my design of experiments. Her summer data yielded promising results that prompted me
to add Cinnamonium cassia to my Engaged Learning drug screen.
It is important to note that medication can be taken to do either of two things: prevent the
development of unhealthful phenotypes or treat the disease after it has already developed.
Note that this screen is designed to assess the preventative effects of these medications
and compounds, not their impact as part of a treatment regimen. Theoretically, an
effective prevention measure should result in halted development of the unhealthy
phenotype in flies fed unhealthy food. In other words, application of an effective
prevention medication should result in a reversion of the “unhealthy” 30% fed phenotype
to be more like that of the “healthier” 5% fed flies.
Preliminary data has been obtained for the known anti-diabetic medication metformin
and the naturally derived compound, curcumin. Curcumin is a component of turmeric, a
spice considered healthful in traditional Indian medicine. The preliminary mass data
obtained for curcumin and metformin is summarized in figure 4.

Figure 3: Effect of (a) metformin and (b) curcumin on the mass of 5% and 30% yeast extract diet
Drosophila. Drug concentration in food increases as color saturation increases: white is the control vehicle,
the light color is [A], the mid-tine is [B], and the most saturated color is [C]. Note that this data is very
preliminary; quantities and error bars shown are the result of single experiments where samples were
obtained in biological quadruplet. Data in (b) was collected independently by Ria Chaabra. All data shown
obtained for female 10 day old flies. Data for sucrose not shown.

In examining results of the drug screen we look for evidence of a phenotype reversion. If
a compound or medication has a preventative effect on the development of the unhealthy
phenotype seen in the control 30% yeast extract, then the flies fed the drug or compound
treated foods in the 30% food should show a dose response curve that trends towards
resembling the healthier, 5% yeast extract fed control flies. Note that such a reversion is
not indicated by this preliminary data for either of these additives. The data for both
metformin and curcumin indicate that the compounds may show potentially drug
concentration dependent response curves.
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The curves seem to indicate a general decreasing trend in mass as more metformin is
added, and a generally increasing trend in mass as more curcumin is added to the food.
However, the effect of either additive is not indicative of a reversion to a healthy
phenotype and is observable in both the healthy and overfed flies. Thus, preliminary
results of the screen indicate that these drugs do not seem to prevent the development of
the unhealthy mass phenotype exhibited by protein overfed Drosophila.
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Section 2. Materials and Methods
2.1 Fly background
The line tGPH was a kind gift from B. Edgar (Fred Hutchinson Cancer Research center,
Seattle, WA). This line expresses a GFP-PH domain in a wildtype w118 background. This
line is the same line used to obtain previously published data on insulin resistance and
metabolite quantification [6].
2.2 Diet
2.2.1 Stock diet
Regular food used for stock maintenance contained approximately 11% sucrose, 3%
yeast, and 5% corn meal by mass. This regular food recipe is a commonly used recipe
that is composed to maximize stock productivity and hardiness.
Fly stocks were raised on approximately 10-15mL regular food topped with a small
amount of activated yeast to encourage stock vitality and virility. All experimental flies
consumed this regular food while developing as larvae but were collected and transferred
to experimental food conditions within 24 hours of eclosion.
2.2.2 Experimental diet
Experimental food was prepared with varying yeast extract and sucrose content as
described previously [6]. Four of these food conditions were employed in this drug
screen: 5% and 30% yeast extract with sucrose constant at 15%, as well as 5% and 30%
sucrose content with yeast extract constant at 15%. Medications and compounds
employed in this drug screen were added to these four kinds of food.
2.3 Medications and natural compounds
The medications tested were glibenclamide, and rosiglitizone and the natural compound
tested was Cinnamomum cassia, commonly known as cassia cinnamon. Preliminary
assays were also performed involving metformin and curcumin, the active ingredient in
turmeric. Each medication or compound was added to fly food in 3 different
concentrations: low [A], mid-level [B], and high [C]. Control vehicle (CV) food was also
created for each drug to account for solvent effects. CV foods have no medication in
them, only 20 mL solvent/L, the same concentration of solvent used in the [C] foods.
This is done to avoid falsely attributing solvent effects to some action of the solvated
drugs. Cinnamon was added as a powder and the cinnamon CV food accordingly contains
no additional liquid.
The specific concentration for each drug is given in table 1. Justification for these
concentrations is given in section 1.3.1
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Name of
medication or
compound

Recommended
daily dose for
human adult
diabetic

Lowest
concentration,
[A]

Mid-level
concentration,
[B]

Highest
concentration,
[C]

Control
vehicle
identity

Metformin
Glibenclamide

500 mg
5 mg

0.8 g / L food
8 mg / L food

2 mg

Cinnamon
Curcumin

Not known
Not known

3.2 mg / L
food
1 g / L food
0.5 g / L food

3.2 g / L food
32 mg / L
food
12.8 mg / L
food
4 g / L food
2 g / L food

H2O
CH3CH2OH

Rosiglitizone

1.6 g / L food
16 mg / L
food
6.4 mg / L
food
2 g / L food
1 g / L food

CH3CH2OH
None
(CH3)2CO

Table 1. Summary of experimental food conditions
2.3.1 Calculation specifics:
Metformin daily recommended daily dose for a diabetic human is 500mg. The human
medication is orally administered. Since flies live on the food they eat and we do not
have technology to force feed them, this dose could not be directly scaled down based on
fly mass. Preliminary experiments determined an effective food-distributed dose to be
1.6g metformin / L food.
To widen the range of conditions in the drug screen, this preliminary dose was halved and
doubled to give additional ([A] and [C]) metformin concentrations of 0.8g/L and 3.2g/L.
Based on this, calculations were done to determine the dose for the other medications and
compounds.
The results of these calculations are summarized in table 1, located in section 1.3

2.4 Fly husbandry
All flies were raised in food-containing clear polystyrene vials topped with rayon plugs.
Flies were kept in an incubator set to maintain 50% humidity and 25 C on a 12 hour
light/dark cycle.
The fly density of stock vials was monitored carefully, lest the environment become
detrimental to larval development and feeding. Stock vials were discarded before the
food was approximately 4 weeks old as a preventative measure against the development
of mites.
2.5 Metabolic assay
Flies were raised for ten days on experimental food conditions. On day 10 they were
collected and weighed. Fly collection is discussed in detail in section 1.5.1. Samples were
prepared by decapitating flies, pulverizing the bodies with a pestle in a hypotonic buffer

Coogan 8

solution, followed by processing the supernatant to quantify metabolites. Sample
preparation is discussed in detail in section 1.5.2. Metabolite quantification is
accomplished using Sigma kits, enzymes and use of absorption spectroscopy. The
biochemistry of the kits is detailed in section 1.5.3.
2.5.1 Experimental conditions
Adult flies were collected under light CO2 anesthesia from stock vials within 24 hours of
eclosion and distributed in groups of 50 onto experimental food conditions. Each
experimental vial contained 25 males and 25 females and approximately 5mL of the
appropriate food. The flies were passed to vials containing new food approximately every
48 hours to ensure consistent food quality. The flies were aged for 10 days in this manner.
2.5.2 Collection and sample preparation
On day 10, flies were anesthetized using CO2, separated by sex, and deposited in groups
of 4 or 5 into preweighed eppendorf tubes. After mass was recorded, samples were
labeled and stored at -80C until further processing could take place. Note that after this
point all samples are kept on ice or colder after collection to avoid decomposition or
uneven enzyme activity.
Samples were flash-frozen in N2(l) and then vortexed to remove heads from bodies and
heads discarded. This is done because eye pigment may interfere with absorption
readings. To finish preparing samples for spectrophotometric analysis of sugars, the
metabolites must first be liberated from the fly body into a protective buffer solution.
Buffer A was added to the bodies in the quantity of 100uL buffer per fly body. Samples
were then ground-up and separated by centrifuge. The supernatant is the completed
sample and was examined using the appropriate Sigma assay kit and enzymes.
Buffer A is often used in our lab for general purposes and so contains a number of
compounds designed to protect proteins from degradation as well as reducing agents. The
composition of buffer A is identical to that of the buffer used in previous lab metabolic
studies [6].
2.5.3 Data collection – Sugar quantification
2.5.3.1 Glucose
To determine glucose levels, each sample is pipetted in 10uL triplicates into 96-well
clear-bottom plates. After plating, reconstituted Sigma glucose assay reagent is added to
each well and the plates are allowed to incubate for 15 minutes. After 15 minutes, the
absorption is measured at 340nm using a plate reader. Data is processed by Gen5
software.
The sigma glucose assay reagent kit contains glucose-6-phosphate dehydrogenase (G-6PDH), hexokinase, ATP and all necessary cofactors. The enzymes in the kit perform the
following reactions:
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+ ATP

Hexokinase

Glucose-6-phosphate + ADP

D - Glucose

Glucose-6-phosphate + β-NADP

G-6-PDH

6-phospho-D-gluconate + β–NADPH

These reactions allow glucose levels to be spectrophotometricly assessed by producing a
proportional amount of NADPH whose concentration can be quantified by determination
of absorbance at 340nm.

2.5.3.2 Glycogen
100uL aliquots of each sample are treated with amyloglucosidase and allowed to incubate
for 45 minutes at 55C. This allows the amyloglucosidase to perform the following
reaction:

Amyloglucosidase

7-11

D - Glucose
Glycogen
This creates a proportional amount of glucose from the glycogen present which allows
for spectrophotometric quantification of the glycogen present using the sigma glucose
assay reagent.
The amyloglucosidase treated sample is then processed as described in 1.5.3.1. After
fitting to a standard curve, total glucose levels are determined, the value of glucose
obtained for non-glycogen glucose is subtracted from the reading to obtain the signal that
can be attributed to glycogen levels. The Gen5 software is programmed to do this
quantification.
2.5.3.3 Trehalose
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100uL aliquots of each sample are treated with trehalase and allowed to incubate for 45
minutes at room temperature. This allows the trehalase to perform the following reaction:

Trehalase

Trehalose

2

D-Glucose

This reaction creates a proportional amount of glucose from the trehalose present which
allows for spectrophotometric quantification of the trehalose present using the sigma
glucose assay reagent.
The trehalase treated sample is then processed and analyzed as described above for the
glycogen determination.
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Section 3. Project results
3.1 Anti-diabetic medications
3.1.1 Glibenclamide

Figure 4. Effect of glibenclamide on metabolism of 5% and 30% sucrose fed Drosophila. Drug
concentration in food increases as color saturation increases: white is the control vehicle, the light color is
[A], the mid-tine is [B], and the most saturated color is [C]. All quantities and error bars shown are the
result of an average of at least three independent experiments where samples were obtained in biological
quadruplet . Extracts for b, c, and d were plated in triplicate. All data shown obtained for female 10 day old
flies.

It is immediately apparent from this data that there is no phenotypic reversion from
unhealthy to healthy phenotype in any of the four tested metabolically relevant
parameters. The data does not indicate that glibenclamide has any effect on the diet
induced metabolic disruption observed in Drosophila.
Another thing that may seem odd in this data is that the CV data trends are not the
same as the trends observed in that data published by Morris et al [6]. This is likely
because the CV food features a large volume of solvent – ethanol in the case of
glibenclamide. This additional ethanol means that the CV food is of a different
composition from the previously examined food and that the CV flies are not directly
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analogous to the flies that served as the baseline for this study. This disparity is not
surprising because ethanol contributes additional calories and volume to the fly
food. The ethanol could also interact somehow with the other food components
which could lead to a different final food composition and, thus, very different
phenotypic effects.

Figure 5. Effect of glibenclamide on metabolism of 5% and 30% yeast extract fed Drosophila. Drug
concentration in food increases as color saturation increases: white is the control vehicle, the light color is
[A], the mid-tine is [B], and the most saturated color is [C]. All quantities and error bars shown are the
result of an average of at least three independent experiments where samples were obtained in biological
quadruplet. Extracts for b, c, and d were plated in triplicate. All data shown obtained for female 10 day old
flies.

The data from varying protein diet flies also does not indicate any phenotypic
reversion. There may be a general, diet independent increasing trend in mass and
glycogen content seen in both the health and overfed flies and statistics need to be
performed to assess this.
The general metabolic trends seen in the CV food for the 5% and 30% yeast extract
flies differs slight from what was observed in foods not containing ethanol by Morris
et al. The only difference is that the glucose content seems to decrease from 5% to
30% rather than remaining constant. Again, differences in phenotype of the CV from
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previous data is not surprising due to the effects arising from the high ethanol
content of the CV food.
3.1.2 Rosiglitizone

Figure 6. Effect of rosiglitizone on metabolism of 5% and 30% sucrose fed Drosophila. Drug
concentration in food increases as color saturation increases: white is the control vehicle, the light color is
[A], the mid-tine is [B], and the most saturated color is [C]. All quantities and error bars shown are the
result of an average of at least three independent experiments where samples were obtained in biological
quadruplet . Extracts for b, c, and d were plated in triplicate. All data shown obtained for female 10 day old
flies.

The data indicates no apparent drug effects.
Note again that the deviation of the CV trends from those anticipated from the
baseline experiments are not surprising due to the ethanol content of the CV food.
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Figure 7. Effect of rosiglitizone on metabolism of 5% and 30% yeast extract fed Drosophila. Drug
concentration in food increases as color saturation increases: white is the control vehicle, the light color is
[A], the mid-tine is [B], and the most saturated color is [C]. All quantities and error bars shown are the
result of an average of at least three independent experiments where samples were obtained in biological
quadruplet . Extracts for b, c, and d were plated in triplicate. All data shown obtained for female 10 day old
flies.

There may be a rosiglitazone induced increase in glucose content seen in b, but it is
not statistically relevant, nor diet dependent.
This data also does not indicate any statistically relevant drug responsive effects.
3.2 Natural compounds
3.2.1 Cinnamonium cassia
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Figure 8. Effect of C. cassia on metabolism of 5% and 30% sucrose fed Drosophila. Drug
concentration in food increases as color saturation increases: white is the control vehicle, the light color is
[A], the mid-tine is [B], and the most saturated color is [C]. All quantities and error bars shown are the
result of an average of at least three independent experiments where samples were obtained in biological
quadruplet . Extracts for b, c, and d were plated in triplicate. All data shown obtained for female 10 day old
flies.

The data in figure 8a indicates a mass phenotype reversion. The other metabolic
phenotypes do not indicate any compound dependent effects at all.
Interestingly, the dose response curve does not show the strongest preventative
result at the highest concentration of C. cassia, but rather at the lowest, [A]. This may
indicate that the doses tested in this drug screen were in excess of the effective dose
and that C. cassia is most beneficial in small amounts.
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Figure 9. Effect of C. cassia on metabolism of 5% and 30% yeast extract fed Drosophila. Drug
concentration in food increases as color saturation increases: white is the control vehicle, the light color is
[A], the mid-tine is [B], and the most saturated color is [C]. All quantities and error bars shown are the
result of an average of at least three independent experiments where samples were obtained in biological
quadruplet . Extracts for b, c, and d were plated in triplicate. All data shown obtained for female 10 day old
flies.

Figure 9a indicates a similar reversion in mass phenotype as is observed in figure 8a.
The other metabolic parameters again seem unaffected by addition of the cinnamon.
Again, the most effective concentration of cinnamon is the lowest, [A]. These data
are nicely consistent with the data seen in figure 8 and implicate C. cassia as a
potential preventative dietary additive to stave off development of an overfed mass
phenotype.
Section 4. Discussion
No statistically relevant phenotype reversion was observed with addition of either
of the known human anti-diabetic medications glibenclamide and rosiglitazone.
Conversely, the data obtained for the natural compound, C. cassia, indicates that it
has preventative effects on the development of increased mass in overfed
Drosophila. This perhaps surprising result could be due to a number of reasons – all
speculative until further tests are done.
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It is possible that the parameters selected for this first drug screen are not sufficient
to observe the action of these drugs in metabolic processes. Fertility assays could
also be added to the screen to provide an additional parameter to further assess the
comparative heath of the medicated flies. Alternatively, insulin resistance could be
directly monitored. This can be done by performing assays such as PH-domain
membrane co-localization asays, Drosophila glucose tolerance tests, or western blots
to quantify the proportion of phosphorylated to unphosphorylated Akt. However,
these assays are not yet straightforward to perform in the lab and are currently
time-consuming, low yield and thus ill-suited for a expansive, wide-scope initial
screen such as this.
It is also possible that the pathway that results in C. cassia affiliated weight-gain
prevention is more evolutionarily old than pathways associated with modern antidiabetics. If this is true, then is it possible that human drugs won’t affect flies in the
same way that they affect humans since the pathway only recently evolved.
It is possible that human anti-diabetics are not intended to prevent the development
of an unhealthy phenotype with poor diet but only to aid in treatment of it, perhaps
in conjunction with the adoption of a healthy diet. The assays performed in this drug
screen all focused on prevention. Another drug screen could be performed where
the flies are raised on healthy and overfeeding food conditions and are then
periodically treated with the drugs and compounds. Results of such a screen would
likely be very different from the results of this prevention-focused drug screen.
Another assay that would be informative is a feeding assay. A feeding assay
quantifies the volume of each food eaten by flies. This assay could help to quantify
exactly how much of each drug or compound each fly ingests which can aid in
determining a mass proportional dose for further testing. This assay would
additionally ascertain whether the observed loss in mass associated with C. cassia is
due to some biological effect of the compound or simply due to the flies eating less
due to the strong taste of C. cassia in the fly food. However, this result is unlikely
because the strongest preventative effect observed was in the [A] cinnamon food.
The [A] food contains cinnamon in an amount 1/4th as concentrated as the [C] food
and, even if they do dislike the taste of cinnamon and that affects their appetites, it
does not make sense that the flies would eat less of the [A] food than the [C] food.
An interesting topic to pursue next is the origin of the weight-gain preventative
effect of C. cassia. The levels of measured metabolites remain essentially constant
across cinnamon concentrations so the phenotype reversion is not due to a loss in
glucose, glycogen or trehalose. This weight loss could be due to a decrease in any
number of other chemicals – ranging from triacylglycerides, to protein, to water.
Further tests must be done to determine the nature of the observed weight loss.
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Section 6. Conclusion
The results of the drug screen indicate Cinnamonium cassia as the most effective of the
three food-additives tested. Cassia cinnamon prevents the development of
unhealthy/excessive diet-induced weight gain. The cinnamon had a significant
preventative effect on the one of the phenotypes measured, while the human anti-diabetic
medications did not have a preventative effect on any of them. These results have helped
to illustrate the potential usefulness of a Drosophila-based drug screen as a means to
identify novel potential anti-diabetics or other potentially useful medications. The results
of my Engaged Learning project can hopefully lead to the development of a more
informative and efficient future Drosophila drug screen. The outcome of this project
constitutes a positive contribution to the larger global health effort.
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